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Abstract
Background: Cathepsin K is a cysteine peptidase known for its importance in osteoclast-mediated bone
resorption. Inhibitors of cathepsin K are in clinical trials for treatment of osteoporosis. However, side effects of first
generation inhibitors included altered levels of related cathepsins in peripheral organs and in the central nervous
system (CNS). Cathepsin K has been recently detected in brain parenchyma and it has been linked to
neurobehavioral disorders such as schizophrenia. Thus, the study of the functions that cathepsin K fulfils in the
brain becomes highly relevant.
Results: Cathepsin K messenger RNA was detectable in all brain regions of wild type (WT) mice. At the protein
level, cathepsin K was detected by immunofluorescence microscopy in vesicles of neuronal and non-neuronal cells
throughout the mouse brain. The hippocampus of WT mice exhibited the highest levels of cathepsin K activity in
fluorogenic assays, while the cortex, striatum, and cerebellum revealed significantly lower enzymatic activities. At
the molecular level, the proteolytic network of cysteine cathepsins was disrupted in the brain of cathepsin K-
deficient (Ctsk
-/-) animals. Specifically, cathepsin B and L protein and activity levels were altered, whereas cathepsin
D remained largely unaffected. Cystatin C, an endogenous inhibitor of cysteine cathepsins, was elevated in the
striatum and hippocampus, pointing to regional differences in the tissue response to Ctsk ablation. Decreased
levels of astrocytic glial fibrillary acidic protein, fewer and less ramified profiles of astrocyte processes, differentially
altered levels of oligodendrocytic cyclic nucleotide phosphodiesterase, as well as alterations in the patterning of
neuronal cell layers were observed in the hippocampus of Ctsk
-/- mice. A number of molecular and cellular
changes were detected in other brain regions, including the cortex, striatum/mesencephalon, and cerebellum.
Moreover, an overall induction of the dopaminergic system was found in Ctsk
-/- animals which exhibited reduced
anxiety levels as well as short- and long-term memory impairments in behavioral assessments.
Conclusion: We conclude that deletion of the Ctsk gene can lead to deregulation of related proteases, resulting in
a wide range of molecular and cellular changes in the CNS with severe consequences for tissue homeostasis. We
propose that cathepsin K activity has an important impact on the development and maintenance of the CNS in
mice.
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Cathepsin K is a mammalian cysteine peptidase that is
sorted to endo-lysosomes and secreted into the extracel-
lular space by certain cell types [1]. It is abundant in
osteoclasts and has a prominent role in bone remodeling
due to its collagenolytic activity [2]. Indeed, cathepsin K
deficiency has been linked to bone disorders such as pyc-
nodysostosis and osteopetrosis [3,4], while the excessive
activity of this enzyme may lead to osteoporosis [5], mak-
ing it a likely target for rational drug design [6-8]. Cathe-
psin K has also been identified in a variety of cell types
other than osteoclasts, such as macrophages [9], bron-
chial and alveolar epithelia [10], gastrointestinal mucosa
[11], and thyroid epithelia [8,12,13], indicating that its
distribution and functions may not be as clearly defined
as initially thought. In the human brain, cathepsin K has
been shown to be present in the choroid plexus [11], and
recent studies have demonstrated its widespread distribu-
tion within neurons and glial cells [14].
To date, cathepsin K distribution and functions in the
mouse CNS are largely unknown, however Ctsk
-/- mice
have not been reported to suffer from severe neurobeha-
vioral phenotypes [15]. The phenomenon of compensa-
tion, i.e. upregulation of related cysteine proteases, has
been suggested to explain the mild phenotypes of mice
with single deficiencies in cysteine cathepsins [1,16]. For
example, enzyme compensation has been previously
observed in the thyroid of Ctsk
-/- mice, where cathepsin
L is significantly upregulated [16], as well as in the brain
of Ctsd
-/- mice, where elevated levels of cathepsin B
have been detected [17]. Moreover, the absence of
cathepsins B and L is known to carry dramatic conse-
quences, including neurodegeneration and brain atrophy
[18,19], while the impact of cathepsin K deficiency on
the mouse CNS has not been investigated in sufficient
detail to date.
Interestingly, basic cathepsin K inhibitors previously
tested in clinical trials have been reported to increase
the activity levels of cathepsins B and L not only in the
liver, kidney and spleen, but also in the CNS of rats
[20], indicating that risk assessments of potential side
effects of cathepsin inhibitor treatments must consider
changes in the proteolytic network of both peripheral
organs and the CNS [8]. Several pathways by which sys-
temically reduced cathepsin K activity could cause
alterations at the level of the brain are plausible: a direct
effect on the metabolism of neurons and glial cells, via
modulation of related enzymes, and/or indirectly, via yet
unknown pathways.
In the present study, we used reverse transcription
polymerase chain reaction (RT-PCR), immunolabeling,
and enzyme histochemistry to demonstrate the expres-
sion of cathepsin K in the mouse brain, both at the
mRNA and at the protein level. Moreover, cathepsin K
activity assays revealed that specific enzyme activity in
the hippocampus was higher than in other brain regions
investigated. Therefore, we used Ctsk
-/- mice to investi-
gate the systemic impact of cathepsin K gene ablation
on the structure and metabolism of the brain. Immuno-
blotting and proteolytic activity assays were employed in
WT and Ctsk
-/- mice to determine activity levels of
related aspartic and cysteine cathepsins with an estab-
lished function in the mouse CNS, and to assess the
levels of a main endogenous cysteine cathepsin inhibitor,
cystatin C. We further addressed the status of major
brain regions including the cerebral cortex, the mesos-
triatal complex, the hippocampus, and the cerebellum,
by using immunoblotting and immunohistochemistry to
evaluate molecular markers of neuronal and glial cells.
Potential behavioral alterations were analyzed in a series
of tests chosen to monitor locomotor activity, anxiety
levels, as well as spatial and non-spatial learning and
memory.
Our results indicate that learning and memory impair-
ments in Ctsk
-/- mice correlated with a combination of
alterations in proteolytic pathways, including significant
reductions of cathepsin B and L levels in cortex and
striatum as well as increased cystatin C levels in stria-
tum and hippocampus. In addition, some of the most
striking observations included immature astrocytes in
hippocampal regions of Ctsk
-/- animals, significant
alterations in neuronal synaptotagmin levels, and promi-
nent changes in the cyclic nucleotide phosphodiesterase
(CNPase) levels of oligodendrocytes, indicating a major
influence of cathepsin K on the cellular metabolism and
function in the mouse CNS. In further support of this
conclusion, a significantly altered distribution and pat-
terning of neurons was observed throughout the hippo-
campus of Ctsk
-/- mice. We propose that the systemic
disruption of cathepsin K activity during development
and adulthood has severe local impacts on the structural
integrity of the mouse CNS, eventually resulting in func-
tional impairments such as learning and memory
deficits.
Results
Cathepsin K identification in the mouse CNS
Several studies have described the presence of cathepsin
K in the CNS of rats [21,22] and in post-mortem human
brain tissue [14,23]. In order to determine whether
cathepsin K is also present in the mouse CNS, tissue
extracts were prepared from cerebral cortex of WT and
Ctsk
-/- mice and examined by RT-PCR. Cathepsin K
mRNA expression was detectable in the cerebral cortex
of WT animals but it was absent in Ctsk
-/- mice (Figure
1A). Cathepsin K mRNA was also present in extracts
prepared from other brain regions, such as hippocam-
pus, striatum/mesencephalon, and cerebellum of WT
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Page 2 of 22mice (Figure 1B), suggesting a broad distribution of
cathepsin K throughout the mouse CNS.
Indirect immunofluorescence studies revealed cathe-
psin K being translated in various brain regions of
WT mice but not in Ctsk
-/- animals (Figure 1C and
1F, cf. 1D, respectively). Moreover, cathepsin K activ-
ity was detectable in vesicles of neurons and glial cells
by enzyme histochemistry [12] performed on cryo-
sections prepared from WT mouse brains (Figure 2A
and 2B, arrows). In particular, the CA2 region of the
hippocampus exhibited signals derived from cathepsin
K substrate conversion both in stratum pyramidale
(Figure 2B, circle) as well as in stratum radiatum
(arrows).
In order to further verify the specificity of the
observed immunofluorescence and cathepsin K sub-
strate conversion reactions, brain tissue homogenates
prepared from WT and Ctsk
-/- mice were used to per-
form cathepsin K activity assays, employing Abz-
HPGGPQ-EDN2pH as a fluorogenic substrate [24]
(Figure 2C - 2F). Cathepsin K activity was detected in
all analyzed brain regions of WT mice (Figure 2C - 2F,
open bars), whereas no activity was detectable in
extracts from brain tissue of Ctsk
-/- animals (grey
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Figure 1 Cathepsin K detection in mouse brain parenchyma. Messenger RNA was isolated from tissue extracts prepared from different brain
regions of WT or Ctsk
-/- mice. RT-PCR reactions with the primer pairs cathepsin K 5’-GCC AGG ATG AAA GTT GTA TG-3’ (forward) and 5’-CAG
GCG TTG TTC TTA TTC C-3’ (reverse) as well as b-actin 5’-GCC AGG ATG AAA GTT GTA TG-3’ (forward) and 5’-CAG GCG TTG TTC TTA TTC C-3’
(reverse) resulted in the amplification of cDNAs of the expected lenghts of approximately 358 bps for cathepsin K specific mRNA (Cath K) and
335 bps for the loading control (b-actin) as revealed by agarose gel (1,5%) electrophoresis. In negative controls, cDNA template was omitted
(Co). Markers of fragment sizes are given in lanes labeled with St. (A) Cathepsin K mRNA was detected by RT-PCR in cerebral cortex tissue from
WT mice (n = 3), but not in samples obtained from Ctsk
-/- mice (n = 3; upper panel). (B) Cathepsin K mRNA was detected in all four investigated
brain regions in WT animals. Bps - base pairs; St - standard DNA ladder; Co - negative RT-PCR control without template; H - hippocampus; Str -
striatum/mesencephalon; Cb - cerebellum; Cx - cortex.Confocal laser scanning micrographs were taken from horizontal sections through choroid
plexus (C), cerebellum (D), cortex (E), and hippocampus (F)o fW To rCtsk
-/- mice as indicated. Sections were prepared from PFA-fixed brain
tissue, immunostained for cathepsin K (green signals, lower panels - middle), counter-stained for nuclear DNA with Draq 5 (red signals, lower
panels - right), and inspected with fluorescence and phase contrast (lower panels - left) microscopy. Cathepsin K protein was immunodetected
in ependymal cells (C, arrows), neurons (F, circles) and glial cells (F, arrows) of WT mice (C and F) but not in negative antibody controls (E)o ri n
sections prepared from Ctsk
-/- brain tissue (D), indicating specificity of cathepsin K immunolabeling. Bars - 100 μm (C-F). CP - choroid plexus; Cb
- cerebellum; Cx - cortex; H - hippocampus.
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Page 3 of 22bars). Importantly, specific cathepsin K activity reached
highest levels in the hippocampus, while the cortex,
striatum/mesencephalon, and the cerebellum exhibited
significantly lower cathepsin K activity in WT mice
(Figure 2C - 2F, open bars).
These results indicated cathepsin K expression and
suggested its enzymatic functionality throughout the
mouse CNS. Hence, we analyzed the impact of cathe-
psin K deficiency on different regions of the mouse
brain at the molecular and cellular level.
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Figure 2 Visualization and quantification of cathepsin K activity in the CNS of WT mice. Confocal laser scanning micrographs were taken
from horizontal sections through cortex (A) and hippocampus (B) of WT mice as indicated. Sections were prepared from 0.5% PFA-fixed brain
tissue after a 45-min reaction with the cathepsin K substrate Z-Gly-Pro-Arg-4MbNA in the presence of NSA as precipitating agent of released
4MbNA under oxygen-free conditions and at pH 6.2 (A, green signals, and B, white signals), and after counter-staining with Draq 5 (A, blue signals).
Cathepsin K activity was detected in vesicles (A, arrows) of both neuronal (B, circle) and glial cells (B, arrows) in the different brain regions analyzed
by enzyme histochemistry. Bars - 100 μm( A), 50 μm( B).Results of cathepsin K activity assays performed with brain tissue lysates of WT (C-F, open
bars, n = 6) and Ctsk
-/- mice (grey bars, n = 3). Cathepsin K activity as determined by cleavage of Abz-HPGGPQ-EDN2ph at pH 5.5 was detected in
the cortex, striatum/mesencephalon, cerebellum, and hippocampus of WT animals. Specific cathepsin K activity levels were calculated by division of
relative fluorescence units (RFU) by the protein content of the respective samples. Specificity of the assay was proven by the use of tissue from
cathepsin K deficient mice. Cathepsin K activity was well detectable in all brain regions analyzed and was highest in the hippocampus (C-F, open
bars). Mean values ± standard deviations are depicted; levels of significance are denoted as ** for p < 0.01; *** for p < 0.001.
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network of related cathepsins in the mouse CNS
It is known that cathepsin networks are able to compen-
sate for the loss of function of individual enzymes. If the
activity of a given cathepsin is inhibited, either chemi-
cally or through gene ablation, related cathepsins might
be upregulated in a cell type- and tissue-specific man-
ner. In order to investigate such potential network
effects induced by the loss of cathepsin K, the protein
and activity levels of cathepsins B, D, and L and the pro-
tein levels of the endogenous cysteine peptidase inhibi-
tor cystatin C were determined by immunoblotting and
proteolytic activity assays in tissue extracts prepared
from different regions of the CNS of WT and Ctsk
-/-
mice.
Cathepsin D protein levels were not altered signifi-
cantly in any of the investigated brain regions (Addi-
tional file 1 and Additional file 2). These results
suggested that the aspartic cathepsin D is not affected
by cathepsin K deficiency. By contrast, protein levels of
cathepsins B (p < 0.001) and L (p < 0.05) (Additional
file 1 and Additional file 2) were significantly reduced in
cerebral cortex of Ctsk
-/- compared to WT mice,
although no significant differences were observed in the
activity levels. The expression levels of the endogenous
inhibitor cystatin C were not altered (Additional file 1).
In the striatum/mesencephalon a significant decrease in
the enzymatic activity of both cathepsins B (p < 0.001)
and L (p < 0.05) was observed while cystatin C levels
were increased (p < 0.05) in this brain region (Addi-
tional file 1). Cathepsin B protein and activity levels
remained unaffected in the cerebellum and hippocam-
pus of Ctsk
-/- mice (Additional file 1). Cathepsin L activ-
ity levels were slightly but not significantly reduced in
cerebellum and hippocampus, although cathepsin L pro-
tein levels were increased in the hippocampus (p < 0.05;
Additional file 1). As in the striatum/mesencephalon, an
increase of cystatin C protein levels (p < 0.001) was
observed in the hippocampus of Ctsk
-/- when compared
to WT mice (Additional file 1). Overall, these results
indicate a deregulated proteolytic network within var-
ious regions of the Ctsk
-/- mouse brain, affecting in par-
ticular cysteine cathepsins.
Impact of cathepsin K deficiency on neuronal markers
and cytoarchitecture in the hippocampus
Deregulated cysteine cathepsins and altered cystatin B/
stefin B and/or cystatin C levels are known to nega-
tively influence the cellular architecture of the mouse
CNS. Both neurons and glia are affected in a number
of mouse models with deficiencies in cysteine cathe-
psins and their endogenous inhibitors, i.e. cystatins B
and C, resulting in dramatic loss of vital brain func-
tions [18,19,25]. Since cathepsin K activity was highest
in the hippocampus and because an impairment of this
brain structure, which is involved in memory forma-
tion and spatial mapping [26], could explain the learn-
ing deficits observed in Ctsk
-/- mice, we further
examined its neuronal patterning. Differentiating
between the dorsal and ventral hippocampus, we
assessed the impact of cathepsin K deficiency by exam-
ining the specific cell patterning, i.e. the numbers and
densities of neurons in the dentate gyrus (DG), CA1,
CA2, and CA3 regions (Figure 3).
Immunohistochemical identification of NeuN-positive
neuronal nuclei in serial cryo-sections and semi-auto-
mated pattern analyses revealed significant differences in
the overall distribution of neurons in all investigated
areas in the dorsal and ventral hippocampus of Ctsk
-/-
mice in comparison to WT (p < 0.001, two-sample Kol-
mogorov-Smirnov test). Neurons were identified and
counted using image analysis software (CellProfiler 2.0,
version 9777). In order to analyze neuronal patterning,
the number of neighbours per neuron within a radius of
7 μm or lower was initially determined. Patterning was
interpreted as dense when neurons were surrounded by
many neighbours, while a sparse patterning was indicated
by a predominance of neurons surrounded by few neigh-
bours. For instance, typical patterning in WT mice in the
DG was characterized by most neurons having 5 neigh-
bours in dorsal versus 6-7 neighbours in ventral hippo-
campus (Figure 3C and 3I, respectively, white bars).
The dorsal DG of Ctsk
-/- mice showed a more densely
packed distribution of neurons, with numerous neurons
surrounded by many neighbours, whereas the opposite
was true for WT mice, in which most neurons had rela-
tively few neighbours (Figure 3C). This different pattern-
ing in Ctsk
-/- mice was most obvious when comparing
the shifts in the maxima of bell-shaped curves profiling
the numbers of neuronal neighbours to those in WT
animals (Figure 3, straight lines profiling white bars ver-
sus dotted lines profiling grey bars). This difference -
more densely packed neurons in Ctsk
-/- mice - was
observed in all investigated areas of the dorsal hippo-
campus (Figure 3C - 3F). Counting also revealed a sig-
nificant increase in the numbers of NeuN-positive cells
in the dorsal DG, CA3, and CA2 regions of Ctsk
-/- com-
pared to WT mice (Figure 3B; p < 0.001; p < 0.05 and p
< 0.001, respectively). A slight, but significant reduction
of NeuN-positive cell nuclei was observed in the dorsal
CA1 region of Ctsk
-/- mice (Figure 3B; p < 0.001).
In contrast to the dorsal part, the ventral hippocampus
showed strikingly different alterations in neuronal num-
bers and distribution in consequence of cathepsin K defi-
ciency. WT animals exhibited more densely packed
neurons in the ventral hippocampus, whereas Ctsk
-/- mice
had more neurons with fewer neighbours in all investi-
gated areas. This is indicative of increased neuronal
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Page 5 of 22spreading in the ventral hippocampus of Ctsk
-/- animals
(Figure 3I - 3L). These alterations were most obvious in
the DG, although the overall neuronal patterning was sig-
nificantly different in all areas of the ventral hippocampus
between the two genotypes. Furthermore, the numbers of
NeuN-positive cells in the ventral DG and CA1 regions of
Ctsk
-/- mice were significantly decreased as compared to
WT controls (Figure 3H; p < 0.001).
Overall, these results suggest subtle changes in the
cytoarchitecture of the hippocampus of Ctsk
-/- mice,
-25
-15
-5
5
15
25
0123456789 1 0
-25
-15
-5
5
15
25
0123456789 1 0
-25
-20
-15
-10
-5
0
5
10
15
20
25
0123456789 1 0
-25
-20
-15
-10
-5
0
5
10
15
20
25
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
N
u
m
b
e
r
s
 
o
f
 
n
e
u
r
o
n
s
 WT
 Ctsk
-/-
0
350
300
250
200
150
100
50
400
DG CA2 CA3 CA1
***
** *
***
-25
-20
-15
-10
-5
0
5
10
15
20
25
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Number of neighbors
N
e
u
N
+
(
%
o
f
a
n
a
l
y
z
e
d
)
 WT
 Ctsk
-/-
-25
-20
-15
-10
-5
0
5
10
15
20
25
0123456789 1 0
WT
ctsk-/-
G DG
CA1
CA2
CA3
-25
-20
-15
-10
-5
0
5
10
15
20
25
0123456789 1 0
-25
-20
-15
-10
-5
0
5
10
15
20
25
0123456789 1 0 1 1
CA3 WT
-/- Ctsk
CA1 WT
-/- Ctsk
WT
-/- Ctsk
CA3 WT
-/- Ctsk
DG WT
-/- Ctsk
WT
-/- Ctsk
CA2 WT
-/- Ctsk
CA1
DG
CA3
CA2
CA1
A C D
EF
J
KL
0
350
300
250
200
150
100
50
DG CA2 CA3 CA1
N
u
m
b
e
r
s
 
o
f
 
n
e
u
r
o
n
s
***
***
B
H
DG WT
-/- Ctsk
I
N
e
u
N
+
 
[
%
 
o
f
 
a
n
a
l
y
z
e
d
]
Number of neighbors Number of neighbors
N
e
u
N
+
 
[
%
 
o
f
 
a
n
a
l
y
z
e
d
]
CA2
Number of neighbors
N
e
u
N
+
 
[
%
 
o
f
 
a
n
a
l
y
z
e
d
]
N
e
u
N
+
 
[
%
 
o
f
 
a
n
a
l
y
z
e
d
]
Number of neighbors
N
e
u
N
+
 
[
%
 
o
f
 
a
n
a
l
y
z
e
d
]
Number of neighbors
N
e
u
N
+
 
[
%
 
o
f
 
a
n
a
l
y
z
e
d
]
Number of neighbors
N
e
u
N
+
 
[
%
 
o
f
 
a
n
a
l
y
z
e
d
]
Number of neighbors
N
e
u
N
+
 
[
%
 
o
f
 
a
n
a
l
y
z
e
d
]
Number of neighbors
Figure 3 Distribution and numbers of neurons in the hippocampus. Confocal laser scanning micrographs were taken from serial horizontal
sections through the dorsal (A) and the ventral hippocampus (G) that were immunostained for NeuN to detect the nuclei of neuronal cells. To
quantify cytoarchitectural variations in the structure of neuronal cell layers, the numbers of neighbours for any given cell were determined as a
measure of density of cell packing. In the dorsal hippocampus of WT animals (n = 6), fewer cells were surrounded by a high number of
neighbours, i.e. neurons showed a more sparse pattern (C-F). By contrast, in Ctsk
-/- mice (n = 6) the ventral part of the hippocampus showed a
significantly more sparse neuronal distribution (G-L). This patterning difference was most pronounced in the DG (C and I), CA2 (E and K) and
CA1 (F and L), although all regions exhibited significant differences in the patterning of the neuronal layer between the two genotypes (p <
0.001, Kolmogorov-Smirnov test). (B) Numbers of neurons were increased in DG, CA3 and CA2 regions in the dorsal part of the hippocampus of
Ctsk
-/- compared to WT mice, whereas neuronal numbers were decreased in the CA1 region of Ctsk
-/- mice. (H) Fewer neurons were observed in
DG and CA1 region in the ventral area of the hippocampus of Ctsk
-/- mice. Bars - 200 μm (A, G). Fluorescence micrographs are displayed in
reverse contrast.
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Page 6 of 22with a gain of neurons in its dorsal part at the expense
of a loss of neurons in its ventral part. Furthermore, a
denser packing of neurons was observed in dorsal hip-
pocampal regions, whereas neurons had a sparser distri-
bution in the ventral hippocampus of Ctsk
-/- mice.
In order to detect other potential abnormalities in
neuronal distribution and function, immunoblotting
experiments were performed to assess CNS levels of the
pre-synaptic marker synaptotagmin and of the
intermediate filament protein NF-M. Densitometry ana-
lysis of immunoblots revealed a significant increase in
synaptotagmin levels in the striatum/mesencephalon of
almost 100% (p < 0.001; Figure 4B), and of approxi-
mately 45% (p < 0.01; Figure 4A) in the cerebral cortex
of Ctsk
-/- mice compared to WT controls. By contrast,
there was a significant decrease in synaptotagmin
amounts in the cerebellum (p < 0.01; Figure 4C) of
Ctsk
-/- mice, while hippocampal synaptotagmin levels
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Figure 4 Neuronal markers in the cerebral cortex, striatum/mesencephalon, hippocampus, and cerebellum. (A, E) Densitometry analysis
of immunoblots prepared from lysates of cerebral cortex of WT (white bars) and Ctsk
-/- mice (grey bars) as indicated. Synaptotagmin levels were
significantly elevated by approximately 45% in Ctsk
-/- mice as compared to WT (A, Ctsk
-/- n = 10; WT n = 13), while analysis of the same samples
showed no significant difference in the amount of NF-M protein (E, Ctsk
-/- n = 8; WT n = 6). (B, F) Densitometry analysis of immunoblots
prepared from lysates of striatum/mesencephalon of WT (white bars) and Ctsk
-/- mice (grey bars) as indicated. Synaptotagmin levels were
elevated in Ctsk
-/- mice by 95% as compared to WT mice (B, Ctsk
-/- n = 10; WT n = 10), while no significant difference was observed in NF-M
protein (F, Ctsk
-/- n = 9; WT n = 11). (C, G) Densitometry analysis of immunoblots prepared from lysates of cerebellum of WT (white bars) and
Ctsk
-/- mice (grey bars) as indicated. Synaptotagmin levels were significantly down-regulated in Ctsk
-/- mice by approximately 55% compared to
WT animals (C, Ctsk
-/- n = 10; WT n = 13), while no significant difference was observed in NF-M protein between the two genotypes (G, Ctsk
-/- n
= 9; WT n = 10). (D, H) Densitometry analysis of immunoblots prepared from lysates of hippocampus of WT (white bars) and Ctsk
-/- mice (grey
bars) as indicated. No significant difference was detected in the amount of synaptotagmin in Ctsk
-/- mice compared to WT (D, Ctsk
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n = 13), while NF-M protein was elevated by approximately 50% in Ctsk
-/- mice compared to WT (H, Ctsk
-/- n = 11; WT n = 9).Protein levels were
determined by densitometry and grey values per area were normalized to the loading control b-tubulin. Bar charts denote mean values
expressed as percent of control ± standard error; levels of significance are denoted as * for p < 0.05; ** for p < 0.01; *** for p < 0.001.
Representative immunoblots are shown in the lower panels; lanes represent separate individuals.
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Page 7 of 22remained unaltered (Figure 4D). For NF-M protein, the
results demonstrated a 50% increase (p < 0.05) in the
hippocampus of Ctsk
-/- mice in comparison to WT con-
trols (Figure 4H).
Impact of cathepsin K deficiency on glial cells
In order to further assess the structural changes induced
by the ablation of cathepsin K, we investigated the status
of the astroglia and oligodendrocytes in the CNS of
Ctsk
-/- mice. We observed a significant increase of
approximately 76% in the expression of the astrocyte
marker glial fibrillary acidic protein (GFAP) in the cere-
bral cortex of Ctsk
-/- mice (p < 0.01, Figure 5A) and a
decrease of 40% in the hippocampus (p < 0.01, Figure
5D) as compared to WT animals. To investigate whether
the marked decrease in GFAP expression might be con-
nected to the differentiation state of astrocytes in the hip-
pocampus of Ctsk
-/- mice, immunohistochemistry was
used to identify GFAP in tissue sections (Figure 5E - 5O).
In all main areas of the hippocampus, including DG,
CA3, CA2, and CA1 areas, reduced GFAP immunolabel-
ing was observed in Ctsk
-/- animals as compared to WT
controls (Figure 5F - 5M). Detailed observation of indivi-
dual astrocytes in the CA1 region also revealed less
numerous and apparently thinner ramifications of Ctsk
-/-
mice astroglia (Figure 5N and 5O). These results
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-/-
mice (grey bars) as indicated. Representative immunoblots are shown in the lower panels; lanes represent separate individuals. (A) GFAP levels in
the cerebral cortex showed a significant increase of approximately 76% in Ctsk
-/- mice compared to WT (A, Ctsk
-/- n = 10; WT n = 13). (B) No
significant difference was observed in the amount of GFAP in striatum/mesencephalon (B, Ctsk
-/- n = 10; WT n = 10). (C) No alterations were
observed in GFAP levels in cerebellum (C, Ctsk
-/- n = 10; WT n = 12). (D) GFAP levels were significantly decreased in hippocampus of Ctsk
-/- mice,
reaching approximately 60% of the values observed in WT (D, Ctsk
-/- n = 10; WT n = 10). (E-O) Developmental status of astrocytes in the
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Fluorescence micrographs are displayed in reverse contrast. Levels of significance are denoted as ** for p < 0.01.
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cytes might underlie the quantified decrease in GFAP
levels.
Densitometry analysis of immunoblots labeled for
CNPase, an oligodendrocyte marker, revealed a signifi-
cant decrease of approximately 42% in CNPase levels in
the striatum/mesencephalon (p < 0.01; Figure 6B) as
well as a decrease of approximately 60% in the hippo-
campus of Ctsk
-/- mice (p < 0.01; Figure 6D). In the cer-
ebellum, however, CNPase levels were increased by
approximately 50% in Ctsk
-/- mice (p < 0.05; Figure 6C).
Since cathepsin K has already been reported to be
involved in the immune response [27], we further ana-
lysed the state of microglia, the resident macrophages of
the CNS [28]. Immunohistochemistry analysis of brain
sections labeled with ionized calcium binding adapter
protein-1 (Iba1), a marker of microglia, showed a
slightly stronger signal in the cerebral cortex of Ctsk
-/-
mice compared to WT controls (p < 0.01; Figure 7A -
7C), whereas no alterations in the Iba1 signal were
detectable in striatum/mesencephalon, cerebellum, or
hippocampus (Figure 7D - 7F).
Behavioral effects of cathepsin K deficiency
The differences in the expression of molecular factors,
particularly those affecting the dopaminergic system (see
below) and the hippocampus (see above), were paral-
leled by observed alterations in the behavior of Ctsk
-/-
mice. The dopaminergic system has been associated
with a wide range of cognitive processes, such as
learning, memory, novelty seeking, reward systems, but
also motor regulation of movement [29]. The hippocam-
pus is well established as vital for learning and memory
as well as emotion-related behavior [30]. Here, we have
tested Ctsk
-/- mice on several measures assessing loco-
motor function and activity throughout the day (Addi-
tional file 3), anxiety (Additional file 4), as well as
learning and memory (Figure 8).
Diurnal variations of in-cage activities of 5 animals per
each genotype were determined over a time period of 3
weeks by a motion-triggered infrared sensor module. No
significant alterations in frequencies of day or night
activities were detectable (Additional file 3), arguing
against any overt deficits in locomotor function of
Ctsk
-/- mice up to an age of 6 months. In an elevated
plus maze task Ctsk
-/- mice spent approximately 36%
(108s out of 300s) in the open arms, whereas WT mice
spent only about 19% (57s out of 300s) of total time in
this area. Correspondingly, while the WT mice showed
ap r o n o u n c e dp r e f e r e n c ef o rt h ec l o s e da r m so ft h e
maze (p < 0.001), in Ctsk
-/- mice this difference was not
detectable (Additional file 4). Moreover, a hole board
test revealed a significant increase in the frequency of
central area crossing in Ctsk
-/- mice, supporting the
hypothesis of reduced anxiety in this genotype (Addi-
tional file 4).
In order to test long-term non-spatial memory, a
novel object recognition test was used. This assessment
included two habituation sessions and a test session,
when a familiar object was replaced with a novel one.
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Figure 6 CNPase status in cerebral cortex, striatum/mesencephalon, cerebellum, and hippocampus. (A-D) Densitometry analysis of
immunoblots prepared from lysates of cerebral cortex, striatum/mesencephalon, cerebellum, and hippocampus of WT (white bars) and Ctsk
-/-
mice (grey bars) as indicated. Representative immunoblots are shown in the lower panels; lanes represent separate individuals. (A) CNPase levels
showed no significant difference in cerebral cortex of Ctsk
-/- mice compared to WT controls (A, Ctsk
-/- n = 10; WT n = 13). (B) In striatum/
mesencephalon CNPase levels were significantly lower in Ctsk
-/- mice, reaching only 58% of values measured in WT (B, Ctsk
-/- n = 10; WT n = 10).
(C) In cerebellum CNPase levels were significantly increased in Ctsk
-/- mice by 50% as compared to WT (C, Ctsk
-/- n = 10; WT n = 11). (D) CNPase
levels in hippocampus were significantly decreased in Ctsk
-/- mice, reaching only 40% of values measured in WT controls (D, Ctsk
-/- n = 11; WT n
= 11). Levels of significance are denoted as * for p < 0.05; ** for p < 0.01.
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Page 9 of 22During the final test session of the novel object recogni-
tion test WT mice spent significantly (p < 0.01) more
time exploring the novel object than they spent with
any of the familiar objects (Figure 8A and 8B, white
bars). By contrast, Ctsk
-/- mice did not show any prefer-
ence for the new object over the familiar ones, indicat-
ing that they could not discriminate the novel element
placed in their familiar environment (Figure 8A and 8B,
grey bars). Interestingly, during all sessions Ctsk
-/- mice
made overall more direct contacts with all objects as
compared to WT animals (data not shown), again indi-
cating decreased inhibition levels.
To further investigate a potential learning deficit of
Ctsk
-/- mice, an elevated multiple choice maze was
used (Figure 8C), which allowed the testing of both
short-term (working memory, WM) and long-term
learning and memory proficiency (reference memory,
RM). A repeated measures ANOVA, with test day as
‘within subjects factor’ and genotype as ‘between sub-
jects factor’,i n d i c a t e dt h a tCtsk
-/- mice made signifi-
cantly more reference memory errors (F(1,21) =
46.981, p < 0.0001) as well as working memory errors
(F(1,21) = 60.273, p < 0.0001), as compared to WT
mice (Figure 8D and 8E). As illustrated in Figures 8D
and 8E, subsequent pairwise comparisons indicated a
clear separation in performance levels for the two gen-
otypes starting from day two (WM) or day five (RM).
While WT mice displayed a normal learning curve
with progressively fewer errors, Ctsk
-/- mice showed
almost no improvement over the duration of the
experiment.
Cathepsin K and the dopaminergic system
The dopaminergic system was investigated due to its
widespread regulatory functions in movement and
motor learning, novelty seeking, and reward processing.
By pooling the striatum and mesencephalon we aimed
to isolate the majority of dopaminergic neurons that
form the mesostriatal pathways [31]. This allowed us to
assess the influence of cathepsin K deficiency on the sta-
tus of the dopaminergic system. Interestingly, densito-
metry analysis of immunoblots labeled for tyrosine
hydroxylase (THase), a marker of catecholaminergic
neurons, revealed a significant 39% overall increase (p <
0.01) in the amount of enzyme in the Ctsk
-/- mice (Fig-
ure 9A). To determine whether the increased levels of
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Page 10 of 22THase may lead to a variation in the levels of dopa-
mine, an ELISA was performed on striatum/mesence-
phalon tissue lysates of WT and Ctsk
-/- mice (Figure
9B). Results showed an average increase of 40% in the
amount of dopamine in Ctsk
-/- mice, however, this
ascending trend did not reach statistical significance.
To rule out that this trend towards higher dopamine
levels in Ctsk
-/- mice might be mediated by decreased
receptor levels, the blotted membranes were probed
with antibodies specific for D2 receptors. Interestingly,
results revealed a significant 30% upregulation (p <
0.001) of D2 receptors in Ctsk
-/- animals in comparison
t oW T( F i g u r e9 C ) .T of u r t h e re x p l o r et h ea p p a r e n t
induction of the dopaminergic system in Ctsk
-/- mice,
we used immunolabeling for THase on brain tissue
sections (Figure 9D and 9E). Confocal fluorescence
microscopy on labeled brain sections revealed an
intense staining of the ventral tegmental area (VTA) of
Ctsk
-/- mice (Figure 9E), whereas less pronounced
immunopositive signals were observed in the VTA of
WT animals (Figure 9D). Intensity analysis of images
of the THase immunolabeled sections, out of which
representative examples are shown (Figure 9D and 9E),
revealed a significant increase in staining intensity for
THase in Ctsk
-/- mice compared to WT controls (Fig-
ure 9F).
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-/- mice compared to WT controls analyzed by a novel object recognition test and by
an elevated multiple choice maze.(A) Experimental setting of the novel object recognition test. Individual mice were placed in the lower left
square, facing the corner. After two habituation sessions, the cube in square 6 was replaced with a shell (objects not drawn to scale). (B) Both
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multiple choice maze. Animals were placed in the starting segment of the maze, and had to make three correct decisions in order to reach the
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session was counted as a working memory error. (D) The learning curves for the two groups were compared on each day of the experiment.
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13) which showed a normal learning curve. (E) Similarly, Ctsk
-/- mice made significantly more reference memory errors starting from day 5 of
testing (C, Ctsk
-/- n = 10; WT n = 13). Levels of significance are denoted as * for p < 0.05; ** for p < 0.01.
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Until recently, the expression of cathepsin K was believed
to be limited to osteoclasts, where it serves a central
function for the proper turnover of long bones [2-4].
Cathepsin K expression has since been shown in a variety
of organs and tissues, and has been connected to numer-
ous other functions, such as proper signalling in the con-
text of the immune response [27] or the processing of b-
endorphin in the brain [23]. Cathepsin K has also been
associated with diseases, such as breast cancer [32] and
schizophrenia [14]. Further functions of cathepsin K with
a widespread impact on physiology and pathophysiology
comprise its contributions in glucose metabolism [33]
and in the processing of one of its natural substrates,
thyroglobulin, thereby mediating liberation of thyroid
hormones [8,12,13,16]. Hence, more detailed investiga-
tions concerning other potential roles of this protease are
essential, especially considering the entry of cathepsin K
inhibitors into clinical treatment of osteoporosis [7,8,34].
The present study aimed to characterize possible func-
tions of cathepsin K in the mouse CNS. Our results
demonstrate that cathepsin K is of considerably higher
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Figure 9 Dopaminergic system markers in the striatum and mesencephalon. (A) Immunoblot analysis of striatum/mesencephalon samples
revealed a significant overall increase in the amount of tyrosine hydroxylase (THase) in Ctsk
-/- mice (n = 10) as compared to WT controls (n =
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of the CNS than previously thought.
From the results of this study, we concluded that the
metabolism and structure of non-neuronal cells were
significantly perturbed in the CNS of Ctsk
-/- animals.
The numbers and the maturation level of astrocytes
were decreased in the hippocampus, while oligodendro-
cyte markers were altered in all analyzed brain regions
except the cortex. The distribution of microglia was
modified only in the cortex. The analysis of neuronal
markers demonstrated that the architecture of the neu-
ronal layers was affected by cathepsin K deficiency in
particular in the hippocampus, a region of the CNS
known for its importance in the regulation of anxiety
and memory. In line with this notion, we observed the
highest specific activity of cathepsin K within this brain
region.
Finally, behavioral studies showed that general locomo-
tor function was not obviously affected in Ctsk
-/- mice, at
least up to the age of 6 months. However, importantly, a
clear impact of cathepsin K deficiency on learning and
memory as well as novelty seeking was revealed.
Linking brain and thyroid functions of cathepsin K
Previously, we have shown that cathepsin K- and L-dou-
ble deficient mice are hypothyroid [16]. Hypothyroid
conditions in early post-natal stages are considered to
negatively affect the development of the CNS [35]. The
abnormal state of cerebellar development during this
period is one of the most obvious indications for severe
hypothyroidism expected to affect adult brain structure
and function significantly [36]. However, cerebellar
development of Ctsk
-/- mice at post-natal day 12 was
indistinguishable from that of WT controls inspected at
the same age. Moreover, thyroxine levels in the blood of
the Ctsk
-/- animals analyzed in our previous study and
those investigated in this study were not significantly
altered in comparison to WT controls. Thus, although
we initially hypothesized that the brain phenotype
described in this study could be directly attributed to a
mild hypothyroidism, we concluded that this hypothesis
was supported neither by the status of early post-natal
development of Ctsk
-/- mice nor by the thyroid hormone
levels determined in the brain of these animals (Sîrbu-
lescu, Dauth, Rehders, Saftig, Jordans, Brix, unpub-
lished). Therefore, we addressed other mechanisms
through which cathepsin K deficiency could have
affected brain development. Because we show herein
that cathepsin K is indeed expressed in the mouse brain
and exhibits proteolytic activity in particular in the hip-
pocampus, we suggest a more direct effect of cathepsin
K deficiency on the mouse CNS development. To
unequivocally distinguish between the effects exerted by
a lack of cathepsin K expression in either the thyroid or
the CNS of mice, organ-specific knock-outs are required
and planned for in our future investigations.
Proteolytic network of the cathepsin K-deficient mouse
CNS
Another pathway which might lead to the pronounced
changes observed in the CNS of Ctsk
-/- mice is via mod-
ulation of related proteases. Compensatory phenomena
underlying the mild phenotypes in mice lacking only
one cysteine cathepsin have been previously described
to occur in a cell type and tissue specific manner [1,8].
Interestingly, while cathepsins B and L, which are clo-
sely related to cathepsin K, showed altered expression
levels in various brain regions, the distantly related
aspartic protease cathepsin D was not affected in the
brain of Ctsk
-/- animals.
Cathepsin B has been associated with neuronal survi-
val by a variety of studies, often with conflicting results.
While cathepsin B of microglial origin has been shown
to serve as an initiator of apoptosis in cultures of hippo-
campal [25] and cortical neurons [37], its absence has
been associated with the death of motor neurons in
amyotrophic lateral sclerosis [38]. A cathepsin B-like
protease has been implicated in dendritic spine collapse
in hippocampal neurons, a process which mediates neu-
ronal synaptic plasticity [39]. A decrease in protein level
or activity of this protease, as observed in the cortex
and striatum/mesencephalon of Ctsk
-/- mice, may there-
fore carry a multitude of consequences, including an
overall enhancement of neuronal activity and/or meta-
bolism. Moreover, the decrease in the activity levels of
cathepsin B correlated with a strong increase in the
levels of synaptotagmin in the striatum/mesencephalon,
suggesting that mechanisms mediating neuronal plasti-
city may be altered in Ctsk
-/- mice.
Cathepsin L, the most similar in structure and func-
tion to cathepsin K, showed a significant decrease in
protein levels in the cortex of Ctsk
-/- mice, while in the
hippocampus an increase was observed. Activity, how-
ever, was moderately decreased in the striatum/mesen-
cephalon, hippocampus, and cerebellum. A series of
studies suggest that cathepsin L is involved in the
maturation of the peptide neurotransmitter enkephalin
from its proenkephalin precursor [40]. In turn, enkepha-
lin has been shown to interact with the dopaminergic
system via D2 receptors [41].
It is interesting to note that we have observed varia-
tions not only in the expression levels of cathepsins B
and L, but also in those of cystatin C, an endogenous
cathepsin inhibitor with extracellular functions [42].
Cystatin C may act as a safe-guarding inhibitor of
cysteine cathepsins after their release from damaged
cells under challenging conditions that involve cell
death [43]. A recent study described cystatin C as
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cal neurons and neuronal cell lines, by inducing autop-
hagy and thereby improving clearance of long-lived
proteins [44]. Cystatin C is also a well established mar-
ker of brain tumours such as gliomas [45]. The signifi-
cance of cystatin C upregulation in the hippocampus of
Ctsk
-/- mice, thus, needs to be further investigated.
Cystatin B, another endogenous cysteine cathepsin
inhibitor with mainly intracellular safe-guarding tasks,
has been shown previously to be required for normal
CNS function. Patients with cystatin B mutations suffer
from the Unverricht Lundborg syndrome, a disorder
associated with epileptic seizures [46]. Because the
cathepsin K-deficient mice exhibited striking neurobeha-
vioral phenotypes, although no signs of epilepsy were
detectable, it will be important in the future to deter-
mine the levels of cysteine cathepsin inhibitors in the
CNS of Ctsk
-/- mice in more detail. In an elegant
approach aiming at the understanding of fine-tuning
proteolytic activities at the genome level, mouse models
of cystatin B deficiency have been crossed with cathe-
psin B- and/or L-deficient animals [19] but not yet with
Ctsk
-/- mice. From the results of this study and those of
Houseweart and colleagues it is, however, clear that
altered ratios of cysteine proteases and their inhibitors
occur in the brain of cysteine cathepsin and/or cystatin-
deficient mice. This is of relevance, considering that cer-
tain inherited mutations or an imbalance of cathepsins
and their endogenous inhibitors in the brain of both
mice and humans have been linked to a number of
severe impairments [18,19,46].
Changes in cellular architecture resulting from cathepsin
K deficiency
In the present work, we observed significantly fewer
astrocytes in the hippocampus and significantly more in
the cortex of Ctsk
-/- mice. Astrocytes have a wide range
of functions that are highly relevant for CNS homeosta-
sis and for proper neuronal function [47,48]. In patholo-
gical situations, including neurodegeneration, activation
of astrocytes as characterized by an overexpression of
GFAP [49], and astrogliosis, an abnormal increase in the
number of astrocytes in damaged areas of the CNS, has
been observed [48]. It is therefore not surprising that
due to changes in maturation and numbers of astrocytes
in Ctsk
-/- mice, other cell types like oligodendrocytes
and neurons may be affected as well. An enhanced sig-
nal of the microglial marker Iba1 was detected in paral-
lel to the increased astrocyte population in the cortex of
Ctsk
-/- animals. This is interesting to note, because
microglia respond to any kind of injury or perturbation
of the CNS and it is believed that they play an essential
role both in acute neuroinflammation and in wound
healing [28,50]. Therefore, higher levels of cortical Iba1
are in line with the observations of higher GFAP levels
in the cortex of Ctsk
-/- mice, thereby putatively hinting
to an altered composition of neurosupportive, neuro-
trophic, and repair-promoting factors in some regions of
the brain.
Dopaminergic system of Ctsk
-/- mice and impact on
neurobehavioral tasks
The overall changes observed in the dopaminergic sys-
tem of Ctsk
-/- mice are of particular interest, since dopa-
mine-mediated neuromodulation is involved in a wide
variety of processes, including movement and motor
learning, novelty seeking, reward processing, fear condi-
tioning, food intake, nociception, and endocrine and
autonomic regulation [29,51,52]. In addition, the dopa-
minergic system is known to have an important role in
both spatial and non-spatial learning [53]. Ctsk
-/- mice
in the present study displayed significantly increased
levels of tyrosine hydroxylase, the initial and rate-limit-
ing enzyme in dopamine biosynthesis [54] and slightly
increased levels of dopamine. Interestingly, D2-receptor
levels were also significantly increased in the striatum/
mesencephalon fraction of Ctsk
-/- mice. Agonists of D2
receptors, such as RU 24213 or quinpirole have been
shown to induce learning impairments [55] and to
decrease anxiety levels in mice [56], respectively. In line
with this notion, in the present study we observed that
Ctsk
-/- mice displayed reduced anxiety levels and impair-
ments in learning and memory skills while exhibiting
enhanced dopamine and increased D2-receptor levels in
comparison to WT controls.
Another mechanism by which cathepsin K might
affect the dopaminergic system could be via its contri-
bution to opioid metabolism. Up-regulation of cathepsin
K expression in rats was directly linked to schizophrenia
induced by treatment with neuroleptics [22]. Interest-
ingly, post-mortem brain tissue from patients with schi-
zophrenia also revealed an increase in the cathepsin K
protein levels [14]. A recent in vitro study has further
shown that cathepsin K can metabolize b-endorphin to
produce met-enkephalin [23]. Met-enkephalin binds to
opiate receptors, leading to an inhibitory effect on dopa-
minergic neurons of the VTA [57]. Accordingly, we pro-
pose that in the absence of cathepsin K activity, less
met-enkephalin would be produced, thus lowering the
inhibitory effect on the VTA dopaminergic neurons and
leading to increased dopaminergic output.
The deregulated cysteine cathepsin network, the
alterations in the cellular architecture of the hippocam-
pus, and the marked metabolic changes observed in
Ctsk
-/- mice which included the dopaminergic system,
prompted us to investigate whether these modifications
resulted in altered behavioral patterns. Since both the
hippocampus and the dopaminergic system are crucially
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ety-related behavior [52], we focused on several tests
addressing these aspects.
It is important to mention that, although cathepsin K
is well known for its implication in bone remodeling
[4,7,58], the mice used in this study did not show any
sign of physical impairment, likely because they were
used at a young age, of up to 6 months. Moreover, a
pilot study on a separate group of Ctsk
-/- and WT ani-
mals (n = 10 for each genotype), using the pole test and
the wire hang test, which assess motor abilities in mice
[59], showed no difference between the two groups [Sîr-
bulescu, Jordans, Lerchl, Saftig, Brix; unpublished
observations].
In a series of tests chosen to assess anxiety, explora-
tion and memory [60-62], Ctsk
-/- mice showed decreased
anxiety and marked spatial and non-spatial learning and
memory impairments. Previous studies have linked an
overactive dopaminergic system to reduced inhibition in
r o d e n t s[ 5 1 , 6 3 ] .O u rr e s u l t so ft h eb e h a v i o r a lt e s t sa r e
therefore in line with the observed increase of dopami-
nergic output in Ctsk
-/- mice. Moreover, the neuronal
cytoarchitecture of the ventral hippocampus was
affected more severely by cathepsin K deficiency than
that of the dorsal hippocampus. The ventral hippocam-
pus has been shown to be involved in regulating emo-
tion-related behavior [64]. Lesions applied in this area
typically lead to reduced anxiety levels in rodents [65].
In addition, the alterations in astrocyte numbers and
maturation states observed in the ventral hippocampus
of Ctsk
-/- animals may contribute to the observed
changes in the distribution and numbers of neurons,
which in turn can lead to the observed behavioral
phenotypes.
Ctsk
-/- mice also showed marked impairments in both
non-spatial learning, as indicated by their inability to
discriminate the introduction of a novel object into a
familiar environment, and in spatial learning tasks, as
demonstrated by the multiple choice maze paradigm.
These results are in agreement with the profound meta-
bolic disruptions found at the level of both the dopami-
nergic system and the hippocampus in these animals,
because the dopaminergic system is known to have an
important role in spatial and non-spatial learning [53]
while the hippocampus is well established as a structure
with an essential role for spatial but also for non-spatial
memory formation [64].
Conclusion
Our results suggest that cathepsin K deficiency in mice
has a multiple-level impact on brain development and
metabolism. To learn more about which cysteine cathe-
psins may be most crucial in substituting for the
decreased cathepsin K activity, it will be important to
identify the natural substrates of cathepsin K in the
CNS. Another approach could include mice with double
deficiencies in cathepsins B and K, or K and L. The use
of such double-deficient animals has been instrumental
in specifying the thyroid functions of cathepsin K and
helped identifying thyroglobulin as one of its natural tar-
gets [1,8,12,13,16].
From this and other recent studies it becomes clear at
this point that the activity of cathepsin K has far-reach-
ing effects throughout various organs. This is of highest
importance in light of recent advances in the develop-
ment of targeted cathepsin K inhibitors, aimed at treat-
ing osteoporosis [8,20,58]. Such compounds are already
in late clinical trials and may be used in patients in the
near future [7,34]. In particular, basic cathepsin K inhi-
bitors such as Balicatib and L-006235 have been
reported to increase the expression and activity levels of
cathepsins B and L in peripheral organs of rats, i.e. liver,
kidney, and spleen, but also in the CNS, by factors
reaching up to 80-fold [6]. Therefore, clinical trials are
now focused on non-basic cathepsin K inhibitors such
as Odanacatib, which is currently in phase III clinical
trials and expected to be completed in 2012 [34,58]. It
has been pointed out, however, that long-term safety
and implications of inhibition of cathepsin K activity are
not fully known at this point [7,8,58].
Interestingly, pycnodysostosis patients suffering from
lifelong absence of cathepsin K activity have been occa-
sionally reported to exhibit, in addition to the abnormal-
ities in bone development, alterations in the CNS such
as hyperplasia of the pituitary, demyelination of the cer-
ebrum, and imbalances between brain growth, vascular
supply, and cerebrospinal fluid pressure, with complica-
tions including sensorineural deafness and frontal por-
encephalic cysts [66].
We suggest that Ctsk
-/- mice provide a useful tool to
better understand the multiple functions that cathepsin
K fulfils in the CNS, in addition to its well-established
roles in peripheral tissues. Considering the above-men-
tioned observations in mice, rats, and humans, it will be
worthwhile to address off-target effects of cathepsin K
inhibitors on the CNS of patients, since a dopaminergic
induction similar to the one observed in this study
could help in the treatment of neurodegenerative disor-
ders, such as Parkinson’s disease, in addition to mana-
ging the symptoms of osteoporosis.
Methods
Animals
All studies were performed on 12-26 weeks-old male
Ctsk
-/- or WT C57Bl/6J mice. The mice were back-
crossed to a congenic C57Bl/6J background in the ani-
mal facility of Jacobs University Bremen, Germany.
Back-crossing was performed over 6 generations for
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ture, and in the studies of metabolic markers. Mice
back-crossed over 8 to 11 generations were used for
PCR, cathepsin immunofluorescence and activity studies.
Generation of the founder Ctsk
-/- mice at University of
Göttingen, Germany, and the genotyping methods are
described elsewhere [4]. For the experiments, mice were
singly housed under standard conditions, with a 12 h/12
h light/dark cycle with lights out at 07:00 p.m. and ad
libitum water and food. Testing was conducted in accor-
dance with institutional guidelines, in S1-laboratories of
Jacobs University Bremen (SfAFGJS Az. 513-30-00/2-15-
32 and 522-27-11/3-1, 05-A20 and A21).
Activity frequency recordings
Analysis of diurnal variations in locomotor activity was
performed as described [67] using 4-6 months old,
male Ctsk
-/- mice and WT controls (n = 5 per geno-
type). Each mouse was singly-housed over a time per-
iod of four weeks, and the activity patterns were
determined for the last three weeks. Movements were
measured via passive infrared sensor detectors (PIDs;
35 × 29.5 × 20 mm; L × W × H) (Conrad Electronic
SE, Hirschau, Germany) which were installed with a
coverage angle of 100° about 13 cm above each cage.
A QuickBasic program was written for the registration
of locomotor activity by PIDs (by courtesy of Dr.
Steinlechner, Tierärztliche Hochschule Hannover, Ger-
many) checking all PID channels and the channel for
the light sensor.
Behavioral testing
Behavioral tests were carried out during the light phase,
between 2 and 5 p.m. The order of testing for the two
genotypes was routinely alternated in order to reduce
effects of diurnal rhythm. Behavioral tests were video-
taped using a webcam positioned directly above the test-
ing area and visualized on a computer screen. Behavior
was coded directly, using Ethograph 2.06 software
(Ritec, St. Petersburg, Russia).
Elevated plus maze
The plus-shaped maze was constructed from opaque
white Plexiglas
®, with 4 arms of equal length (50 cm)
and width (5 cm) extending from a central square
platform (side: 5 cm). Closed arms were bordered by
side walls (height: 20 cm), while the two open arms
did not have any lateral boundaries. The maze was
elevated on poles 50 cm above ground. Each mouse
was placed on the central platform, facing the same
closed arm, and allowed to explore the maze for a sin-
gle trial lasting 5 min, after which it was returned to
its home cage. The time spent in closed or open arms
as well as on the central platform was recorded for
each individual.
Hole board test
A square wooden box of 60 × 60 × 35 cm was used for
testing. The inside of the box was painted black, and the
floor was divided into nine equal squares. Four holes
with a diameter of 3.5 cm were located at the corners of
the central square. The floor was elevated 10 cm above
the bottom of the box. Individual animals were placed
in the lower left corner of the enclosure, facing the wall,
and allowed to explore freely for 3 min, after which the
mice were returned to the home cage. The number of
head dips into holes, rearings, and squares crossed were
recorded as described above, the latter serving as a gen-
eral index of locomotor activity. The number of center
crossings was recorded and considered as an indirect
measure of anxiety.
Novel object recognition test
A box similar to the one described above was used,
however lacking the floor holes. Four different objects
were placed in squares 1, 4, 6 and 8 during the test: a
wooden cube (side: 3.5 cm), a plastic Lego
® corner
(side: 2 cm, height: 1.5 cm), a plastic Lego
® house shape
(length: 4 cm, width: 2 cm, height: 3 cm) and a gyps
ellipsoid (long radius: 5 cm; short radii: 3.5 cm). Addi-
tionally, for the object substitution test, a shell (length: 5
cm, width: 2.5 cm, height: 2 cm) was used as a novel
object. Mice were placed in the testing arena, as
described above. During the first day of testing, the ani-
mals were given two consecutive 3-min habituation ses-
sions, with an inter-session interval of one hour. On the
next day, one of the objects (cube) was replaced with an
unfamiliar one (shell). Mice were again allowed to
explore the setting for 3 min. The total time spent in
each of the squares containing an object was
determined.
Elevated multiple-choice maze
The maze was constructed out of opaque white Plexi-
glas
® strips, with a width of 5 cm and a total length of
265 cm, elevated on poles with a height of 50 cm. Ani-
mals were placed in the starting segment of the maze,
and had to make three correct decisions in order to
reach the exit point. There they could descend via a
wire net into a cage containing a house, which was
placed on the floor and was not readily visible from the
maze. The maximum duration of one trial was 3 min.
Testing was conducted daily, over an interval of 12 days.
An entry into a maze segment that was outside the cor-
rect route (0-1-4-7-E-F in this order, see Figure 8C) was
counted as a reference memory error, while backtrack-
ing into any already visited segment within a given ses-
sion was counted as a working memory error.
Tissue sampling
Mice were anesthetized, the abdominal and thoracic
cavities were opened and the abdominal aorta was cut.
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NaCl supplemented with 200 IU heparin (Braun Mel-
sungen AG, Melsungen, Germany). The head and neck
regions were immediately separated and placed on ice.
Brain samples
The brain was removed and the two hemispheres were
separated. One hemisphere was placed in 4% PFA in
200 mM HEPES, pH 7.4, and left overnight at 4°C, then
cryo-preservation was carried out by incubating in 0.5
M and afterwards in 1 M sucrose solution in phosphate-
buffered saline (PBS), pH 7.4, for each another 24 h at
4°C. Tissue samples were embedded in Tissue Freezing
Medium (Jung, through Leica Microsystems) and stored
at -20°C. Alternatively, tissue was frozen using the liquid
nitrogen-isopentane method and stored at -80°C until
sectioning. The other hemisphere was immediately dis-
sected on ice and the cortex, hippocampus, cerebellum,
and striatum together with the mesencephalon and
diencephalon (referred to as striatum/mesencephalon
fraction) were separated and snap-frozen in liquid
nitrogen.
SDS-PAGE, immunoblotting, immunodetection and
densitometry
Protein extraction
Tissue samples were homogenized in ice-cold PBS con-
taining 0.5% Triton X-100, using a Potter S homogeni-
z e r( S a r t o r i u s ,G ö t t i n g e n ,G e r m a n y )a t1 , 0 0 0r p mf o r5
min. Further extraction was performed by placing the
resulting homogenates in a rotary mixer for 40 min at
4°C. After centrifugation at 10,000 ×-g and 4°C for 10
min, the supernatants were removed and stored at -20°
C.
Gel electrophoresis
The protein content of all samples was determined
using the Neuhoff assay [68]. Tissue lysates were nor-
malized to equal amounts of protein, boiled in sample
buffer and separated on 12.5% acrylamide gels.
Immunoblotting and immunodetection
Separated proteins were semi-dry blotted onto nitrocellu-
lose membrane. Blocking was done overnight at 4°C
using 5% milk powder in PBS containing 0.3% Tween-20
(PBST). Primary antibodies, sheep anti-tyrosine hydroxy-
lase (AB1542, Chemicon, Billerica, MA, USA), rabbit
anti-dopamine D2 receptor (ab21218, Abcam, Cam-
b r i d g e ,U K ) ,m o u s ea n t i - G F A P( G 3 8 9 3 ;S i g m a - A l d r i c h
Chemie GmbH, Taufkirchen, Germany), mouse anti-
CNPase (C5922; Sigma), chicken anti-synaptotagmin
(AB9356; Chemicon), rabbit anti-cystatin C (9300; kind
gift of Dr. Magnus Abrahamson, Lund, Sweden), goat
anti-mouse cathepsin B (GT15047, Neuromics, through
Acris Antibodies, Herford, Germany), rabbit anti-human
cathepsin D (IM16, Calbiochem-Novabiochem GmbH,
Bad Soden, Germany), and goat anti-mouse cathepsin L
(GT15049, Neuromics) were applied for 1.5 h at room
temperature. The appropriate secondary antibodies,
either HRP-conjugated donkey anti-sheep IgG (713-035-
003, Immunoresearch Europe L t d . ,S u f f o l k ,U K ) ,g o a t
anti-rabbit IgG (4050-05, Southern Biotech, Birmingham,
Alabama, USA), rabbit anti-goat IgG (6160-05; Southern
Biotech),or goat anti-chicken IgG (6100-05; Southern
Biotech) were applied for 1 h at room temperature. As a
loading control, membranes were stripped and re-probed
for either glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), using a rabbit anti-GAPDH primary antibody
(ab9485, Abcam), or for b-tubulin, using a rabbit anti-b-
tubulin primary antibody (T-3526, Sigma), and an HRP-
conjugated goat anti-rabbit secondary antibody, as
described above. Immunoreactions were visualized by
enhanced chemiluminescence on CL-XPosure film
(Pierce through Perbio Science Europe, Bonn, Germany)
or on Hyperfilm MP (GE Healthcare Europe GmbH,
Munich, Germany).
Densitometry
Films from two to seven different blots for each immu-
nodetection and each animal were scanned with a trans-
mitted-light scanner (Desk Scan II version 2.9; Hewlett-
Packard Co., Palo Alto, California, USA) and evaluated
densitometrically using TINA version 2.09d (Raytest Iso-
topen-Messgeräte GmbH, Straubenhardt, Germany).
The measured optical density/mm
2 values, after back-
ground subtraction, were normalized within each blot
by dividing individual values to the average of the WT
mice values in the respective blot. For normalization b-
tubulin was used. For averaging over different immuno-
blot intensities varying from membrane to membrane
values are given as percent of control, e.g. the average of
the WT values were set to 100% and each single value
(WT and Ctsk
-/-) was then compared to this average
value. For quantification of cathepsin protein levels (see,
Additional file 1) the bands representing the mature
forms, i.e. single chain, or heavy and light chains of two-
chain-forms of the respective cathepsins were analyzed
by densitometry (see also, Additional file 2).
PCR
Brain tissue from WT (cortex, striatum/mesencephalon,
hippocampus and cerebellum) and Ctsk
-/- (cortex) mice
was homogenized in PBS containing 0.5% Triton X-100
as described above. After centrifugation at 12,000 rpm,
pellets were collected and used for RNA extraction
using Trizol (Invitrogen), chloroform and isopropanol as
described in [69]. RNA concentration was determined
by NanoDrop™ (Kiesker, Steinfurt, Germany). Reverse
transcription was performed using 2U reverse transcrip-
tase (Quiagen, Hilden, Germany) and 1 μg RNA accord-
ing to the manufacturer’s instructions. The following
primers were used for amplification: Cathepsin K 5’-
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CAG GCG TTG TTC TTA TTC C-3’ (reverse); b-actin:
5’-GCC AGG ATG AAA GTT GTA TG-3’ (forward),
5’-CAG GCG TTG TTC TTA TTC C-3’ (reverse).
Cathepsin K cDNA was amplified by an initial denatura-
tion of 1 min at 95°C, followed by 35 cycles, each con-
sisting of 1 min at 95°C (denaturation), 1 min at 53.4°C
(annealing), and 1 min at 72°C (elongation). The ampli-
fication of b-actin cDNA consisted of 26 repeats of 30-
sec cycles of denaturation at 95°C, annealing for 20 sec
at 58°C and elongation for 45 sec at 72°C. The reactions
were terminated through incubation for 7 min at 72°C.
ELISA
For determining levels of dopamine, commercially avail-
able ELISA kits were used. Tissue extracts from frac-
tions including the dopaminergic system were first
acidified by adding HCl to a final concentration of 0.01
N and then used in a dopamine enzyme immunoassay
(Dopamine Research EIA, KAPL10-5300, BioSource Eur-
ope S.A., Nivelles, Belgium) according to the manufac-
turer’s manual.
Cathepsin activity assays
Cysteine cathepsins
The enzyme activity assay was performed as described
in [70] and with variations as detailed in [71] by moni-
toring cleavage of 5 μM cathepsin B substrate N-benzy-
loxycarbonyl-arginyl-arginine-7-amido-4-methylcou-
marin (Z-Arg-Arg-AMC; Bachem Distribution Services
GmbH, Weil am Rhein, Germany) at pH 6.0 for 10 min
at 40°C, 1.5 μM CA-074 cathepsin B-specific inhibitor
(Merck Biosciences GmbH, Darmstadt, Germany) plus 5
μM cathepsin L substrate N-benzyloxycarbonyl-phenyla-
lanyl-arginine-7-amido-4-methylcoumarin (Z-Phe-Arg-
AMC; Bachem Distribution Services GmbH) at pH 5.5
for 10 min at 30°C, and 5.6 μM cathepsin K substrate ο-
aminobenzoic acid-histidyl-prolyl-glycyl-glycyl-prolyl-
glutaminyl- N-(2,4-dinitrophenyl)-ethylene diamine
(Abz-HPGGPQ-EDN2ph) [12,24] at pH 5.5 for 10 min
at 30°C. Negative controls were run in parallel with the
addition of 10 μM of the cysteine protease inhibitor
E64. Reactions were terminated by adding stop solutions
and fluorescence was measured with a Tecan GENios
Reader (Tecan Deutschland GmbH, Crailsheim, Ger-
many), using an excitation wavelength of 360 nm and
reading the emission at 465 nm for cathepsin B and L
activity assays, whereas cathepsin K activity was deter-
mined with an excitation at 320 nm and emission set to
420 nm.
Cathepsin D
Activity was tested as previously described [72] with var-
iations as detailed in [71] by monitoring cleavage of
cathepsin D substrate 7-methoxycoumarin-4-yl-acetyl-
glycyl-lysyl-prolyl-isoleucyl-phenylalanyl-phenylalanyl-
arginyl-leucyl-lysine (2, 4-dinitrophenyl)-D-arginine
(MOCAc-Gly-Lys-Pro-Ile-Leu-Phe ~ Phe-Arg-Leu-Lys
(Dnp)-D-Arg-NH2; Merck Biosciences GmbH) at pH 4.0
for 10 min at 40°C. Controls were incubated in addition
with 1 μM pepstatin A (Sigma-Aldrich Chemie GmbH,
Taufkirchen, Germany). Reactions were stopped and
fluorescence was measured using an excitation wave-
length of 328 nm and reading the emission at 393 nm.
Analysis
All assays were performed in duplicates and repeated 2-
4 times. For each genotype, three to six different mice
were used, except for cathepsin B and L striatum/
mesencephalon, where eight mice were used. Relative
fluorescence units (RFU) of controls were subtracted
from the values of the corresponding samples. In order
to allow averaging over several assays, RFU values were
normalized by the averages of the WT measurements
within a given assay. For calculation of specific cathepsin
K activity, RFU values were divided by protein contents
of the respective samples.
Immuno- and enzyme histochemistry
Brain hemispheres were cut horizontally on a cryostat
(Leica CM1900, Leica Microsystems) into 16 μm sec-
tions and thaw-mounted serially on microscope slides.
Residual embedding material was washed out prior to
the staining procedure by incubating slides overnight in
PBS at 4°C. Blocking of non-specific binding sites on
sections was performed at room temperature by a 4 h-
or 1.5 h-incubation with 3% bovine serum albumin
(Albumin Fraction V, Roth, Karlsruhe, Germany) includ-
ing 0.3% or 0.1% Triton X-100 in calcium and magne-
sium-free PBS (CMF-PBS), respectively. Primary
antibodies, mouse anti-tyrosine hydroxylase (MAB318,
Chemicon), mouse anti-GFAP (G3893; Sigma), mouse
anti-Neuronal Nuclei (NeuN) (MAB377, Millipore, CA,
USA), mouse anti-human cathepsin K (IM55, Calbio-
chem-Novabiochem GmbH), and rabbit anti-Iba1 (016-
20001; Wako Pure Chemical Industries, Japan) antibo-
dies were applied overnight at 4°C. Secondary antibo-
dies, goat anti-mouse IgG conjugated with Alexa 546
(A11018, Invitrogen through Molecular Probes, Karls-
ruhe, Germany) or Alexa 488 (A11017, Invitrogen), and
goat anti-rabbit IgG conjugated with Alexa 488
(A11034, Invitrogen) were applied for 4 h on brain sec-
tions at room temperature in a moisturized chamber.
Cathepsin K activity assays by enzyme histochemistry
Cryo-sections of 0.5% PFA fixed brain tissue were
washed several times in PBS to remove embedding med-
ium before pre-incubation for 5 min at 37°C in reducing
reaction buffer consisting of 0.2 M ammonium acetate,
0.125 mM b-mercaptoethanol, 0.1 mM EDTA-Na2,0 . 5
MN a 2HPO4, pH 6.2, and subsequent incubation under
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with 1 mM cathepsin K substrate Z-glycinyl-prolyl-argi-
nyl-4-methoxy-b-naphthylamine (Z-Gly-Pro-Arg-
4MbNA; J1105, Bachem) for 45 min in the presence of
1 mM nitrosalicyl aldehyde (NSA) as the precipitating
agent of released 4MbNA as previously described [12].
Thereafter, sections were washed and mounted in PBS,
and the insoluble precipitates were visualized at an exci-
tation of 435 - 490 and the emission set to 520 - 530
nm by META-detection with the LSM 510 (see below).
Microscopy and analysis
Confocal images were taken using a Zeiss LSM 510
META laser-scanning microscope equipped with Argon
and Helium-Neon lasers (Carl Zeiss GmbH, Oberko-
chen, Germany). Optical sections were taken with a pin-
hole opening of 1 Airy unit and at a resolution of 1,024
× 1,024 pixels, using LSM 5 software (version 3.2; Carl
Zeiss).
Analysis of hippocampus sections
A total of 278 horizontal sections from the ventral hip-
pocampus and 582 horizontal sections of the dorsal hip-
pocampus were immunolabeled for NeuN and analyzed.
For each genotype, six different mice were used. Confo-
cal images taken from the DG, CA1, CA2, and CA3
regions were analyzed using CellProfiler 2.0, version
9777 [73]. The image processing and analysis command
pipelines were run under MATLAB (The MathWorks,
Inc., Natick, MA). Briefly, images were exported as grey-
scale pictures and neuronal nuclei were identified
according to intensity by application of thresholding and
smoothing filters. The number of nuclei per image and
the number of nearest neighbours within a 15-pixel (~7
μm) distance of any given nucleus were determined. In
order to take into account that neuronal numbers may
differ, special care was taken in order to analyze com-
parable numbers of neurons.
Statistical analysis
Normal distribution of all data sets was verified using
the Kolmogorov-Smirnov test. Two-tailed Student’st -
test was used to assess group differences for data from
the elevated plus maze, hole board test, immunoblot
densitometry, ELISA and morphometric analyses. For
analyzing data from the novel object recognition test
and elevated multiple choice maze, repeated measures
analysis of variance (ANOVA) was used, with signifi-
cance levels for multiple comparisons corrected using
the Bonferroni procedure. For assessing differences in
the neuronal distributions the Kolmogorov-Smirnov and
the Mann-Whitney U test were used. All data are
shown as mean ± standard error of the mean, except for
Figure 2 and Additional file 3, which show mean ± stan-
dard deviation.
Additional material
Additional file 1: Proteolytic network in specific brain regions of
Ctsk
-/- mice as compared to WT controls. Densitometry analysis of
immunoblots and results of cathepsin activity assays performed with
brain tissue lysates of WT (open bars) and Ctsk
-/- mice (grey bars) (A-D,
A’-D’) Cathepsin D protein levels were unaltered and its activity as
determined by cleavage of MOCAc-Gly-Lys-Pro-Ile-Leu-Phe ~ Phe-Arg-
Leu-Lys (Dnp)-D-Arg-NH2 at pH 4.0 was slightly elevated in cerebellum of
Ctsk
-/- mice, but these changes were not significant (A, Ctsk
-/- n = 20, WT
n = 19; A’, Ctsk
-/- n = 5, WT n = 5; B, Ctsk
-/- n = 15, WT n = 17; B’, Ctsk
-/-
n = 5, WT n = 5; C, Ctsk
-/- n = 16, WT n = 17; C’, Ctsk
-/- n = 5, WT n = 5;
D, Ctsk
-/- n = 8, WT n = 12; D’, Ctsk
-/- n = 5, WT n = 5). (E-H, E’-H’)
Cathepsin B protein levels were decreased in cerebral cortex of Ctsk
-/-
mice, while its activity as determined by cleavage of Z-Arg-Arg-AMC at
pH 6.0 was reduced only in striatum/mesencephalon of these mice (E,
Ctsk
-/- n = 18, WT n = 19; E’, Ctsk
-/- n = 5, WT n = 5; F, Ctsk
-/- n = 14, WT
n = 15; F’, Ctsk
-/- n = 8, WT n = 8; G, Ctsk
-/- n = 16, WT n = 18; G’, Ctsk
-/-
n = 5, WT n = 5; H, Ctsk
-/- n = 13, WT n = 17; H’, Ctsk
-/- n = 5, WT n = 5).
(I-L, I’-L’) Cathepsin L protein levels were down-regulated in cerebral
cortex, while its Z-Phe-Arg-AMC cleaving activity at pH 5.5 was decreased
in striatum/mesencephalon (I, Ctsk
-/- n = 19, WT n = 19; I’, Ctsk
-/- n=5 ,
WT n = 5; J, Ctsk
-/- n = 13, WT n = 15; J’, Ctsk
-/- n = 8, WT n = 8; K, Ctsk
-/-
n = 16, WT n = 18; K’, Ctsk
-/- n = 5, WT n = 5; L, Ctsk
-/- n = 13, WT n =
17; L’, Ctsk
-/- n = 5, WT n = 5). (M-P) Protein levels of the endogenous
cysteine peptidase inhibitor, cystatin C, were significantly upregulated in
striatum/mesencephalon and hippocampus of Ctsk
-/- mice (M, Ctsk
-/- n=
15, WT n = 17; N, Ctsk
-/- n = 14, WT n = 12; O, Ctsk
-/- n = 14, WT n = 17;
P, Ctsk
-/- n = 17, WT n = 16). The results indicated deregulated cysteine
cathepsins B and L and cystatin C levels depending on the particular
brain region analyzed in Ctsk
-/- mice, whereas the neuroprotective
aspartic protease cathepsin D remained unaffected. Levels of significance
are denoted as * for p < 0.05; ** for p < 0.01; *** for p < 0.001.
Additional file 2: Cathepsin and cystatin C status in the cerebral
cortex, striatum/mesencephalon, cerebellum, and hippocampus.
Representative immunoblots for densitometry analysis shown in
Additional file 1; lanes represent separate individuals. (A-D) Cathepsin D
(heavy chain and light chain) expression. (E-H) Cathepsin B (single chain)
expression. (I-L) Cathepsin L (heavy chain) expression. (M-P) Cystatin C
expression. Corresponding loading controls (b-tubulin) for each
immunoblot are shown in the lower panels.
Additional file 3: Locomotor activity analysis by infrared sensor
module recordings of activity frequencies. Mice were singly housed
over a time period of four weeks and recordings were taken by
integrating activity frequencies over time intervals of 10 min, each, as
detected by the infrared sensor module throughout weeks 2-4. Ctsk
-/-
mice (grey dotted line) exhibited no obvious differences in locomotor
activity and diurnal rhythm in comparison to WT controls (straight black
line) (Ctsk
-/- n = 5; WT n = 5).
Additional file 4: Elevated plus maze and hole board test. (A) Ctsk
-/-
mice (grey bars) spent approximately 36% of the total time in the open
arms, a marked increase compared to the WT controls (open bars). In
addition, while the WT mice showed a pronounced preference for the
closed arms of the maze, this difference was not significant in Ctsk
-/-
mice. (B) The hole board test revealed a significant increase in the
frequency of central area crossing in Ctsk
-/- mice compared to WT
controls (A and B, Ctsk
-/- n = 10; WT n = 12). Levels of significance are
denoted as * for p < 0.05; *** for p < 0.001.
List of abbreviations
4MβNA: 4-methoxy-β-naphtylamine; Abz-HPGGPQ-EDN2pH - ο-aminobenzoic
acid-histidyl-prolyl-glycyl-glycyl-prolyl-glutaminyl-N-(2,4-dinitrophenyl)-
ethylene diamine; bps: basepairs; CathB: cathepsin B; CathD: cathepsin D;
CathK: cathepsin K; CathL: cathepsin L; CysC: cystatin C; Cb: cerebellum;
CNPase: cyclic-nucleotide-phosphodiesterase; CNS: central nervous system;
Co: control; Ctsd
-/-: cathepsin D deficient; Ctsk
-/-: cathepsin K deficient; Cx:
cerebral cortex; D2R: dopamine type 2 receptors; DG: dentate gyrus; ELISA:
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NeuN: neuronal nuclei; NF-M: neurofilament medium; NSA:
nitrosalicylaldehyde; PID: passive infrared sensor detectors; RT-PCR: reverse
transcriptase - polymerase chain reaction; RM: reference memory; St:
standard; Str or striatum/mesenceph. - striatum/mesencephalon; THase:
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